Luciano Candilio

Dr. Luciano Candilio

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in International Journal of Cardiology
Verified
Journal Article
Closed access
ODOzan M. Demir
Ozan M. Demir
LCLuciano Candilio
Luciano Candilio
DFDaniel Fuster
Daniel Fuster
RMRobert Muga
Robert Muga
GBGiuseppe Barbaro
Giuseppe Barbaro
LALorenzo Azzalini
Lorenzo Azzalini

31 December 2014 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
LCLuciano Candilio
Luciano Candilio
AMAbdul Malik
Abdul Malik
CACon Ariti
Con Ariti
SKSherbano A Khan
Sherbano A Khan
MBMatthew Barnard
Matthew Barnard
NRNeil Roberts
Neil Roberts
Retrograde perfusion into coronary sinus during coronary artery bypass graft (CABG) surgery reduces the need for cardioplegic interruptions and ensures the distribution of cardioplegia to stenosed vessel territories, therefore enhancing the delivery of cardioplegia to the subendocardium. Peri-operative myocardial injury (PMI), as measured by the rise of serum level of cardiac biomarkers, has been associated with short and long-term clinical outcomes. We conducted a retrospective analysis to investigate whether the combination of antegrade and retrograde techniques of cardioplegia delivery is associated with a reduced PMI than that observed with the traditional methods of myocardial preservation. Fifty-four consecutive patients underwent CABG surgery using either antegrade cold blood cardioplegia (group 1, n = 28) or cross-clamp fibrillation (group 2, n = 16) or antegrade retrograde warm blood cardioplegia (group 3, n = 10). The study primary end-point was PMI, evaluated with total area under the curve (AUC) of high-sensitivity Troponin-T (hsTnT), measured pre-operatively and at 6, 12, 24, 48 and 72 hours post-surgery. Secondary endpoints were acute kidney injury (AKI) and inotrope scores, length of intensive care unit (ICU) and hospital stay, new onset atrial fibrillation (AF) and clinical outcomes at 6 weeks (death, non-fatal myocardial infarction, coronary artery revascularization, stroke). There was evidence that mean total AUC of hsTnT was different among the three groups (P = 0.050). In particular mean total AUC of hsTnT was significantly lower in group 3 compared to both group 1 (-16.55; 95% CI: -30.08, -3.01; P = 0.018) with slightly weaker evidence of a lower mean hsTnT in group 3 when compared to group 2 (-15.13; 95% CI -29.87, -0.39; P = 0.044). There was no evidence of a difference when comparing group 2 to group 1 (-1.42,; 95% CI: -12.95, 10.12, P = 0.806). Our retrospective analysis suggests that, compared to traditional methods of myocardial preservation, antegrade retrograde cardioplegia may reduce PMI in patients undergoing first time CABG surgery.

4 January 2018 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
LALorenzo Azzalini
Lorenzo Azzalini
AKAris Karatasakis
Aris Karatasakis
JSJames Spratt
James Spratt
PTPéter Tajti
Péter Tajti
RRRobert F. Riley
Robert F. Riley
KMKambis Mashayekhi
Kambis Mashayekhi

4 May 2021 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
TKThomas A. Kite
Thomas A. Kite
ALAndrew Ladwiniec
Andrew Ladwiniec
COColum G. Owens
Colum G. Owens
ACAlexander Chase
Alexander Chase
ASAadil Shaukat
Aadil Shaukat
UIUK‐ReVasc Registry Investigators
UK‐ReVasc Registry Investigators
Objectives To describe outcomes following percutaneous coronary intervention (PCI) in patients who would usually have undergone coronary artery bypass grafting (CABG). Background In the United Kingdom, cardiac surgery for coronary artery disease (CAD) was dramatically reduced during the first wave of the COVID‐19 pandemic. Many patients with “surgical disease” instead underwent PCI. Methods Between 1 March 2020 and 31 July 2020, 215 patients with recognized “surgical” CAD who underwent PCI were enrolled in the prospective UK‐ReVasc Registry (ReVR). 30‐day major cardiovascular event outcomes were collected. Findings in ReVR patients were directly compared to reference PCI and isolated CABG pre‐COVID‐19 data from British Cardiovascular Intervention Society (BCIS) and National Cardiac Audit Programme (NCAP) databases. Results ReVR patients had higher incidence of diabetes (34.4% vs 26.4%, P = .008), multi‐vessel disease with left main stem disease (51.4% vs 3.0%, P < .001) and left anterior descending artery involvement (94.8% vs 67.2%, P < .001) compared to BCIS data. SYNTAX Score in ReVR was high (mean 28.0). Increased use of transradial access (93.3% vs 88.6%, P = .03), intracoronary imaging (43.6% vs 14.4%, P < .001) and calcium modification (23.6% vs 3.5%, P < .001) was observed. No difference in in‐hospital mortality was demonstrated compared to PCI and CABG data (ReVR 1.4% vs BCIS 0.7%, P = .19; vs NCAP 1.0%, P = .48). Inpatient stay was half compared to CABG (3.0 vs 6.0 days). Low‐event rates in ReVR were maintained to 30‐day follow‐up. Conclusions PCI undertaken using contemporary techniques produces excellent short‐term results in patients who would be otherwise CABG candidates. Longer‐term follow‐up is essential to determine whether these outcomes are maintained over time.

27 December 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
SASalaheldin Agamy
Salaheldin Agamy
SZSheref Zaghloul
Sheref Zaghloul
Zahid KhanZahid Khan
Zahid Khan
ASAhmed Shahin
Ahmed Shahin
RKRamy Kishk
Ramy Kishk
LCLuciano Candilio
Luciano Candilio
Background: Coronary artery disease (CAD) remains a significant health challenge, placing a heavy burden on people and healthcare systems worldwide. Objectives: This narrative review aims to provide a comprehensive overview of recent advancements in the diagnosis, intervention, and pharmacological management of CAD, with a focus on emerging technologies shaping its future. Methods: This is a narrative review that synthesises information from diverse sources, including clinical trials, systematic reviews, meta-analyses, and preclinical studies, to provide a comprehensive overview of the current landscape and emerging trends in CAD management. The literature included in this review was sourced from original research articles and review papers published between January 2010 and December 2025. Results: Early detection has been transformed by non-invasive imaging, such as PCAT, and the addition of invasive and non-invasive FFR technology enables quicker and more accurate diagnoses. Biomarkers, such as high-sensitivity troponin, have further improved the precision of acute coronary syndrome detection, enhancing early intervention. In interventional cardiology, new-generation drug-eluting stents (DESs) have lowered restenosis rates, whereas robotic-assisted percutaneous coronary intervention (PCI) offers precision and reduced operator radiation exposure. Furthermore, the efficacy of drug-coated balloons (DCBs) has been established in the management of in-stent restenosis, and their application in de novo coronary lesions and bifurcation anatomy remains promising. Looking ahead, nanomedicine promises targeted plaque reduction and vascular repair, while 3D-bioprinted blood vessels offer durable, biocompatible grafts for surgical applications. Pharmacological developments, including modern cholesterol-lowering drugs, have also been crucial in achieving cholesterol targets. Conclusions: Despite significant advancements in diagnosis, intervention, and pharmacotherapy, several critical challenges remain, including the need for validated biomarkers and imaging modalities to identify vulnerable atheroma before symptoms arise. Continued research is essential to improve patient outcomes and address the global burden of CAD.

1 October 2017 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
LCLuciano Candilio
Luciano Candilio
SMSatoru Mitomo
Satoru Mitomo
MCMauro Carlino
Mauro Carlino
ACAntonio Colombo
Antonio Colombo
LALorenzo Azzalini
Lorenzo Azzalini